This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Canopy Growth (CGC) Gains on Hemp Legalization, Institutional Interest
by Ryan McQueeney
Shares of Canopy Growth (CGC) were up more than 6% in late afternoon trading Tuesday, as investors expressed optimism about the Senate's hemp legalization bill and management's comments about interest from institutional investors.
The Zacks Analyst Blog Highlights: Altria, Cronos, Constellation, Canopy Growth and ETFMG Alternative Harvest
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Altria, Cronos, Constellation, Canopy Growth and ETFMG Alternative Harvest
Cronos Group (CRON) Soars on C$2.4B Investment from Altria
by Zacks Equity Research
Cronos Group (CRON) receives a significant boost with C$2.4-billion equity investment from tobacco giant Altria Group.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $31.02, moving -1.21% from the previous trading session.
Here's Why You Should Hold Constellation Brands Stock Now
by Zacks Equity Research
Constellation Brands (STZ) is a favored stock, owing to its robust surprise trend, strength in the beer business and solid business growth plans, including investment in Canopy Growth.
Cronos-Altria Deal Boost Marijuana ETF: Will This Continue?
by Sweta Killa
Altria investment in Canadian cannabis producer Cronos sparked a rally in the broad cannabis sector and the its ETF. Will the trend continue?
Are Options Traders Betting on a Big Move in Canopy Growth (CGC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
Are There Any Dividend-Paying Cannabis Stocks?
by Ryan McQueeney
Cannabis stocks have been one of the investing world's top stories in 2018, but for many, these speculative plays are far too unpredictable. Are there any stable, dividend-paying marijuana stocks to buy right now?
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $33.33 in the latest trading session, marking a -0.66% move from the prior day.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $31.70 in the latest trading session, marking a +0.48% move from the prior day.
Legal Pot Shops & Likely IPOs: Is Hemp the Next Big Thing?
by Nitish Marwah
Increasing tolerance and gradual legalization of marijuana has been an increasing trend across America.
Top and Flop ETFs of Last Week
by Sanghamitra Saha
Inside the winning and losing ETFs of the last week.
Company News For Nov 15, 2018
by Zacks Equity Research
Companies In The News Are: CGC,GOOS,SNAP,PENN
What Went Wrong With the Marijuana ETF on Wednesday?
by Sanghamitra Saha
Downbeat earnings have weighed on the marijuana ETF lately. Should you buy the dip or wait on the sidelines?
Canopy Growth Corporation (CGC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -484.62% and -30.27%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Cannabis Stocks Reporting Earnings & News from HD, AAPL, TSN
by Ryan McQueeney
Ryan McQueeney discusses the latest trade war developments and recaps earnings results from Home Depot and Tyson Foods. He also touches on Apple's supplier concerns. Later, the host chats with Dave Bartosiak about the marijuana stocks reporting earnings this week.
The Earnings Charts of 3 Top Cannabis Stocks
by Tracey Ryniec
The cannabis stocks are hot but will their earnings reports be too?
Can Canadian Market Drive Canopy Growth (CGC) Q2 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) is poised to gain from continued strength in the Canadian medical cannabis market in the fiscal second quarter.
Will Product Innovations Aid Canopy Growth (CGC) in Q2?
by Zacks Equity Research
Canopy Growth (CGC) is expected to benefit from a solid top-line contribution in the Canadian medical cannabis market.
The Zacks Analyst Blog Highlights: Tilray, Canopy Growth, Cronos and ETFMG Alternative Harvest
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Canopy Growth, Cronos and ETFMG Alternative Harvest
Is the Options Market Predicting a Spike in Canopy Growth (CGC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
Why Marijuana Stocks & ETF Soared Today
by Neena Mishra
Pot stocks soared today as Jeff Sessions' exit and midterm elections have created a more favorable political environment for the industry.
Earnings Preview: Canopy Growth Corporation (CGC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Canopy Growth Corporation (CGC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $37.04, moving +0.41% from the previous trading session.
The Zacks Analyst Blog Highlights: Tilray, Cronos, Canopy Growth, GW Pharmaceuticals and Constellation Brands
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Cronos, Canopy Growth, GW Pharmaceuticals and Constellation Brands